| 000 | 01425 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517233525.0 | ||
| 264 | 0 | _c20190513 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1468-1331 | ||
| 024 | 7 |
_a10.1111/ene.13788 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGilhus, N E | |
| 245 | 0 | 0 |
_aMaternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. _h[electronic resource] |
| 260 |
_bEuropean journal of neurology _c12 2018 |
||
| 300 |
_a1402-1409 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAutoantibodies |
| 650 | 0 | 4 | _aFamily |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xadverse effects |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aMyasthenia Gravis _xdrug therapy |
| 650 | 0 | 4 | _aNeuromuscular Diseases |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 |
_aPrenatal Exposure Delayed Effects _ximmunology |
| 650 | 0 | 4 |
_aPyridostigmine Bromide _xadverse effects |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _ximmunology |
| 650 | 0 | 4 |
_aReceptors, Cholinergic _ximmunology |
| 700 | 1 | _aHong, Y | |
| 773 | 0 |
_tEuropean journal of neurology _gvol. 25 _gno. 12 _gp. 1402-1409 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ene.13788 _zAvailable from publisher's website |
| 999 |
_c28754837 _d28754837 |
||